newsfilter
← Earnings
Earnings Releases·

Galectin Therapeutics — Q3 2026 Earnings Summary

  • Reported net loss of $3.6 million ($0.04/share) for Q3 2026, a significant improvement from $8.2 million ($0.13/share) in Q2 2026, driven by reduced R&D expenses and lower interest costs.
  • Completed a major capital structure simplification by converting $105.8 million in debt to equity, reducing total liabilities to $46.4 million and extending cash runway through June 2027.
  • Filed the registrational Phase 3 protocol for belapectin in advanced MASH with the FDA in Q3 2026, achieving alignment on key design elements including the primary endpoint and dosing regimen.
  • Presented positive NAVIGATE trial data at AASLD showing a 15.9% placebo-adjusted improvement in portal hypertension risk, while maintaining Fast Track designation for the lead program.
Company
GALECTIN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology